Zobrazeno 1 - 10
of 105
pro vyhledávání: '"Martin Weisser"'
Autor:
Johannes Bloehdorn, Andrejs Braun, Amaro Taylor-Weiner, Billy Michael Chelliah Jebaraj, Sandra Robrecht, Julia Krzykalla, Heng Pan, Adam Giza, Gulnara Akylzhanova, Karlheinz Holzmann, Annika Scheffold, Harvey E. Johnston, Ru-Fang Yeh, Tetyana Klymenko, Eugen Tausch, Barbara Eichhorst, Lars Bullinger, Kirsten Fischer, Martin Weisser, Tadeusz Robak, Christof Schneider, John Gribben, Lekh N. Dahal, Mathew J. Carter, Olivier Elemento, Dan A. Landau, Donna S. Neuberg, Mark S. Cragg, Axel Benner, Michael Hallek, Catherine J. Wu, Hartmut Döhner, Stephan Stilgenbauer, Daniel Mertens
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-18 (2021)
Chronic lymphocytic leukemia has been studied using multiple levels of omics data. Here, the authors use exome sequencing, SNP, protein and gene expression data to identify distinct biologic tumor subtypes with heterogeneous prognostic impact after c
Externí odkaz:
https://doaj.org/article/fc98052a777c445bb5de9e2a3b17c607
Autor:
Michael A. Cannarile, Martin Weisser, Wolfgang Jacob, Anna-Maria Jegg, Carola H. Ries, Dominik Rüttinger
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 5, Iss 1, Pp 1-13 (2017)
Abstract The tumor-permissive and immunosuppressive characteristics of tumor-associated macrophages (TAM) have fueled interest in therapeutically targeting these cells. In this context, the colony-stimulating factor 1 (CSF1)/colony-stimulating factor
Externí odkaz:
https://doaj.org/article/d178a458f1254b0b92d2840ec5a6df0e
Autor:
Enriqueta Felip, Juan-Miguel Cejalvo, Wolfgang Jacob, Tania Fleitas Kanonnikoff, Alejandro Navarro Mendivil, Maria Martinez Garcia, Alvaro Taus Garcia, Natasha Leighl, Ulrik Lassen, Morten Mau-Soerensen, Celine Adessi, Francesca Michielin, Ian James, Maurizio Ceppi, Max Hasmann, Martin Weisser
Publikováno v:
ESMO Open, Vol 4, Iss 4 (2019)
Purpose This study investigated the safety and clinical activity of lumretuzumab, a humanised antihuman epidermal growth factor receptor 3 (HER3) monoclonal antibody, in combination with carboplatin and paclitaxel in first-line treatment of patients
Externí odkaz:
https://doaj.org/article/2579db173c034d929a05203fd637d4c5
Autor:
Denis Collins, Wolfgang Jacob, Juan Miguel Cejalvo, Maurizio Ceppi, Ian James, Max Hasmann, John Crown, Andrés Cervantes, Martin Weisser, Birgit Bossenmaier
Publikováno v:
PLoS ONE, Vol 12, Iss 5, p e0177331 (2017)
Bidirectional cross talk between members of the human epidermal growth factor family of receptors (HER) and the estrogen receptor (ER) is believed to underlie resistance mechanisms that develop in response to treatment with anti-HER agents and endocr
Externí odkaz:
https://doaj.org/article/6e469a908d9d4d14aeb5dc57af83056d
Autor:
Martin Weisser
This book introduces a methodology and research tool (DART) that make it possible to carry out advanced corpus pragmatics research using dialogue corpora enriched with pragmatics-relevant annotations. It first explores the general use of spoken corpo
Autor:
Carmelo Carlo-Stella, Rita Mazza, Salomon Manier, Thierry Facon, Sung-Soo Yoon, Youngil Koh, Simon J Harrison, Jeremy Er, Antonio Pinto, Francesco Volzone, Giulia Perrone, Paolo Corradini, Titouan Cazaubiel, Cyrille Hulin, Cyrille Touzeau, Philippe Moreau, Enrique M. Ocio, Carmen Maria Montes Gaisan, Rakesh Popat, Sarah Leong, Fritz Offner, Paula Rodriguez Otero, Ana Alfonso-Pierola, Ann-Marie E Bröske, Iryna Dekhtiarenko, Hans-Joachim Helms, Sara Belli, Eva Rossmann, Tanja Fauti, Jan Eckmann, Tom Moore, Meike Schneider, Wolfgang Jacob, Martin Weisser, Martin Hutchings, Caroline Hasselbalch Riley
Publikováno v:
Blood. 140:397-399
Autor:
Michael Dickinson, Giuseppe Gritti, Carmelo Carlo-Stella, Harriet S Walter, David Carlile, Nicole Getzmann, Samira Curdt, Emma Harrop, Abiraj Keelara, Koorosh Korfi, Remi Labatut, Francesca Michielin, Sarah Louise Mycroft, Tom Moore, Robert Nutbrown, Giuseppe Palldino, Matt Whayman, Johannes Sam, Martin Weisser, Katharina E Lechner, Franck Morschhauser, Martin Hutchings
Publikováno v:
Blood. 140:3818-3820
Autor:
Céline Adessi, Martin Weisser, Andreas Schneeweiss, Max Hasmann, Georgina Meneses-Lorente, Christine McIntyre, Fethallah Benmansour, Régine Gérard, Blandine Avignon, Sabine Wilson, Sven Kronenberg, Wolfgang Jacob, Francesca Michielin, Annie Moisan
1. Supplementary Figure 1. Illustration of tubes area detection as rectangles based on the bright field channel. 2. Supplementary Figure 2. Diarrhea severity during combination treatment with lumretuzumab (RO5479599), pertuzumab and paclitaxel in pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54db68e27685812d3371a76fa3b6a2f4
https://doi.org/10.1158/1535-7163.22505418
https://doi.org/10.1158/1535-7163.22505418
Data from Mechanistic Investigations of Diarrhea Toxicity Induced by Anti-HER2/3 Combination Therapy
Autor:
Céline Adessi, Martin Weisser, Andreas Schneeweiss, Max Hasmann, Georgina Meneses-Lorente, Christine McIntyre, Fethallah Benmansour, Régine Gérard, Blandine Avignon, Sabine Wilson, Sven Kronenberg, Wolfgang Jacob, Francesca Michielin, Annie Moisan
Combination of targeted therapies is expected to provide superior efficacy in the treatment of cancer either by enhanced antitumor activity or by preventing or delaying the development of resistance. Common challenges in developing combination therap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cf3ecdffdb68901e0ce6f6d3303c1fb6
https://doi.org/10.1158/1535-7163.c.6538053.v1
https://doi.org/10.1158/1535-7163.c.6538053.v1
Autor:
Ulrik N. Lassen, Martin Weisser, Birgit Bossenmaier, Francesca Michielin, Celine Adessi, Lori Steiner, Maitram Nguyen, Rajiv Dua, Suzana Vega-Harring, Ian James, Georgina Meneses-Lorente, Maurizio Ceppi, Marlene Thomas, Sabine Wilson, Jan H.M. Schellens, Sang-We Kim, Enriqueta Felip, Antonio Calles, Ji-Youn Han, Stefan Sleijfer, Maja J. De Jonge, Marlies H.G. Langenberg, Martijn P. Lolkema, Andres Cervantes, Tania Fleitas, Alvaro Taus, Maria Martinez-Garcia, Morten Mau-Sorensen, Emile E. Voest, Wolfgang Jacob, Didier Meulendijks
Purpose: This study investigated the safety, clinical activity, and target-associated biomarkers of lumretuzumab, a humanized, glycoengineered, anti-HER3 monoclonal antibody (mAb), in combination with the EGFR-blocking agents erlotinib or cetuximab i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::318985d039f3af8aedc62fa7c6e52f8e
https://doi.org/10.1158/1078-0432.c.6527064.v1
https://doi.org/10.1158/1078-0432.c.6527064.v1